Search Result

Results for "

chemotaxis inhibitor

" in MedChemExpress (MCE) Product Catalog:

By Targets:	5-HT Receptor (1) Akt (3) Apoptosis (1) Aryl Hydrocarbon Receptor (1) Bacterial (2) c-Kit (1) Calcium Channel (4) CCR (32) Chemerin Receptor (1) Complement System (2) CXCR (7) Cytochrome P450 (1) DOCK (1) Dopamine Receptor (1) Drug Derivative (2) Drug Metabolite (1) Endogenous Metabolite (5) ERK (2) Formyl Peptide Receptor (FPR) (5) GPR84 (1) Histamine Receptor (13) HIV (1) HuR (1) Isotope-Labeled Compounds (2) JNK (1) Leukotriene Receptor (3) Ligands for Target Protein for PROTAC (1) mRNA (1) Na+/K+ ATPase (1) NF-κB (3) p38 MAPK (2) PGE synthase (1) Phosphatase (2) Phospholipase (2) PKC (2) Prostaglandin Receptor (1) Proteasome (1) Protein Arginine Deiminase (1) Reactive Oxygen Species (ROS) (1) Reference Standards (9) RET (1) SARS-CoV (1) Ser/Thr Protease (1) Serotonin Transporter (1) Src (2) TrxR (1) VEGFR (1)
By Research Areas:	Cancer (20) Cardiovascular Disease (4) Endocrinology (12) Infection (7) Inflammation/Immunology (66) Metabolic Disease (2) Neurological Disease (7)
Oligonucleotides:	Chemokine & Receptors (1) mRNA (1)

Inhibitors & Agonists

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

Natural
Products

Isotope-Labeled Compounds

Oligonucleotides

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-17042

Cetirizine 3 Publications Verification	Histamine Receptor	Inflammation/Immunology Endocrinology
Cetirizine, a second-generation antihistamine and the carboxylated metabolite of hydroxyzine, is a specific, orally active and long-acting histamine H1-receptor antagonist. Cetirizine marks antiallergic properties and inhibits eosinophil chemotaxis during the allergic response .

HY-103364A

C-021 dihydrochloride 2 Publications Verification	CCR	Inflammation/Immunology
C-021 dihydrochloride is a potent CC chemokine receptor-4 (CCR4) antagonist. C-021 dihydrochloride potently inhibits functional chemotaxis in human and mouse with IC₅₀s of 140 nM and 39 nM, respectively. C-021 dihydrochloride effectively prevents human CCL22-derived [ ³⁵S]GTPγS from binding to the receptor with an IC₅₀ of 18 nM .

HY-101283

HCH6-1 5 Publications Verification	Formyl Peptide Receptor (FPR)	Inflammation/Immunology
HCH6-1 is a potent and competitive dipeptide antagonist of Formyl peptide receptor 1 (FPR1). HCH6-1 inhibits chemotaxis, superoxide anion generation, and elastase release in human neutrophils specifically activated by fMLF (an FPR1 agonist). HCH6-1 has protective effects against acute lung injury (ALI) in vivo and can be used for the research of FPR1-involved inflammatory lung diseases .

HY-17042A

Cetirizine dihydrochloride 3 Publications Verification P071	Histamine Receptor	Inflammation/Immunology Endocrinology Cancer
Cetirizine dihydrochloride, a second-generation antihistamine and the carboxylated metabolite of hydroxyzine, is a specific, orally active and long-acting histamine H1-receptor antagonist. Cetirizine dihydrochloride marks antiallergic properties and inhibits eosinophil chemotaxis during the allergic response .

HY-12807

FIPI 5 Publications Verification 5-Fluoro-2-indolyl deschlorohalopemide	Phospholipase	Cardiovascular Disease Neurological Disease Inflammation/Immunology Cancer
FIPI is a phospholipase D (PLD) inhibitor with an IC₅₀ for PLD1 and PLD2 of about 25 nM. FIPI regulates cytoskeletal recombination, cell diffusion and chemotaxis. FIPI can be used in cancer research. In addition, FIPI can enhance the secretion and aggregation of platelet dense particles, inhibit thrombosis, reduce ischemic stroke infarct volume and improve nerve function .

HY-P4744

LL-37 amide 2 Publications Verification	Formyl Peptide Receptor (FPR) Bacterial	Infection Cancer
LL-37 amide is a selective agonist of formyl peptide receptor-like FPRL1, effectively inhibiting periodontal pathogens (ED₉₉=8.5-8.7 μg/mL). LL-37 amide exerts its bactericidal effect by activating FPRL1-mediated immune cell chemotaxis and disrupting bacterial cell membrane integrity. It can also regulate inflammatory responses (inhibiting the release of factors such as TNF-α) and promote angiogenesis. Amidation modification reduces its sensitivity to serum inhibition and improves its stability. LL-37 amide possesses key activities in bactericidal action, immunomodulation, and wound healing, and is mainly used in research on infection-related diseases such as periodontal disease and deep tissue injuries (pressure ulcers), and wound healing .

HY-15724

Vercirnon 3 Publications Verification GSK-1605786; CCX282-B; Traficet-EN	CCR Ligands for Target Protein for PROTAC	Inflammation/Immunology Endocrinology
Vercirnon (GSK1605786A) is an orally bioavailable, selective, and potent antagonist of CCR9. Vercirnon inhibits CCR9-mediated Ca ²⁺ mobilization and chemotaxis on Molt-4 cells with IC₅₀ values of 5.4 and 3.4 nM, respectively. Vercirnon is selective for CCR9 over CCR1-12 and CX3CR1-7 (IC₅₀s>10 μM for all). Vercirnon is an equipotent inhibitor of CCL25-directed chemotaxis of both splice forms of CCR9 (CCR9A and CCR9B) with IC₅₀ values of 2.8 and 2.6 nM, respectively .

HY-109011

Rosiptor 3 Publications Verification AQX-1125	Phosphatase	Cancer
Rosiptor (AQX-1125) is a selective and orally active phosphatase SHIP1 activator with anti-inflammatory effects. Rosiptor (AQX-1125) inhibits Akt phosphorylation, inflammatory mediator production and leukocyte chemotaxis in vitro .

HY-148853

SRI-42127 1 Publications Verification	HuR	Others
SRI-42127 is a HuR translocation inhibitor. HuR is an RNA regulator that binds to AREs, and HuR translocations promote the production of inflammatory cytokines in glial cells. However, SRI-42127 can destroy mRNA stability and inhibit gene promoter activation. SRI-42127 also inhibits microglial cell activation and attenuates recruitment/chemotaxis of neutrophils and monocytes .

HY-P99520

Vilobelimab CaCP-29, IFX-1	Complement System SARS-CoV	Infection Inflammation/Immunology
Vilobelimab (CaCP-29, IFX-1) is a monoclonal anti-C5a antibody to the allergen C5a, a pro-inflammatory complement division product that plays a central role in mediating organ dysfunction. Vilobelimab acts as a C5a inhibitor, inhibiting neutrophil activation, chemotaxis, and reducing inflammatory signalling, and may be used in studies related to sepsis, COVID-19, etc .

HY-N0634

Cimifugin 1 Publications Verification Cimitin	NF-κB	Inflammation/Immunology
Cimifugin (Cimitin) is a bioactive component of Cimicifuga racemosa, a Chinese herb. Cimifugin suppresses allergic inflammation by reducing epithelial derived initiative key factors via regulating tight junctions . Cimifugin reduces the migration and chemotaxis of RAW264.7 cells and inhibits the release of inflammatory factors and activation of MAPKs and NF-κB signaling pathways induced by LPS .

HY-106381

Aurothiomalate sodium	PKC	Inflammation/Immunology Cancer
Aurothiomalate sodium is the tetrameric form of Aurothiomalate sodium (HY-106381). Aurothiomalate sodium acts as an inhibitor of PKCI and TrxR1. Aurothiomalate sodium disrupts the PKCI-Par6-Rac1 signaling pathway, and also inhibits TrxR1 activity, TNFα-induced NF-κB activation, and the expression of pro-inflammatory genes. Aurothiomalate sodium blocks Kras-mediated BASC expansion and lung tumor growth, inhibits anchorage-independent growth and tumorigenicity of lung cancer cells, and suppresses neutrophil chemotaxis, phagocytosis, and leukocyte extravasation. Aurothiomalate sodium can be used in research related to rheumatoid arthritis and non-small cell lung cancer .

HY-153128

DOCK2-IN-1	DOCK Drug Derivative	Inflammation/Immunology
DOCK2-IN-1 (Compound 3) is an analog of CPYPP (HY-110100) and a DOCK2 inhibitor (IC₅₀ = 19.1 μM). DOCK2-IN-1 binds to the DHR-2 domain of DOCK2 and inhibits its mediated Rac guanine nucleotide exchange factor activity. DOCK2-IN-1 blocks chemokine receptor- and antigen receptor-mediated activation of Rac in lymphocytes. DOCK2-IN-1 significantly inhibits chemotaxis and T cell activation. DOCK2-IN-1 can be used in the research of transplant rejection and organ-specific autoimmune diseases .

HY-122219

R243 3 Publications Verification	CCR	Inflammation/Immunology
R243 is a potent and selective CCR8 antagonist. R243 inhibits CCL₁/CCR8 interaction and inhibits CCR8 signaling and chemotaxis. R243 has antinociceptive and anti-inflammatory effects .

HY-108323

CCR2 antagonist 4 Maximum Cited Publications 6 Publications Verification Teijin compound 1	CCR	Inflammation/Immunology
CCR2 antagonist 4 (Teijin compound 1) is a potent and specific CCR2 antagonist, with IC₅₀s of 180 nM for CCR2b. CCR2 antagonist 4 potently inhibits MCP-1-induced chemotaxis with an IC₅₀ of 24 nM .

HY-103362

CCR2 antagonist 4 hydrochloride Maximum Cited Publications 6 Publications Verification Teijin compound 1 hydrochloride	CCR	Inflammation/Immunology
CCR2 antagonist 4 hydrochloride (Teijin compound 1 hydrochloride) is a potent and specific CCR2 antagonist, with IC₅₀s of 180 nM for CCR2b. CCR2 antagonist 4 hydrochloride potently inhibits MCP-1-induced chemotaxis with an IC₅₀ of 24 nM .

HY-153450

JBI-589	Protein Arginine Deiminase	Cancer
JBI-589 is a non-covalent PAD4 isoform-selective inhibitor with oral bioavailability. JBI-589 reduces CXCR2 expression and blocks neutrophil chemotaxis. JBI-589 reduces primary tumor and metastases, and enhances the anti-tumor effect of checkpoint inhibitors. JBI-589 can be used in cancer research .

HY-16992A

W-54011 Maximum Cited Publications 6 Publications Verification	Complement System Reactive Oxygen Species (ROS)	Inflammation/Immunology
W-54011 is a potent and orally active non-peptide C5a receptor antagonist. W-54011 inhibits the binding of ¹²⁵I-labeled C5a to human neutrophils with a K_i value of 2.2 nM. W-54011 also inhibits C5a-induced intracellular Ca ²⁺ mobilization, chemotaxis, and generation of ROS in human neutrophils with IC₅₀s of 3.1 nM, 2.7 nM, and 1.6 nM, respectively .

HY-P991567

VX5 VX5/5261	CXCR	Inflammation/Immunology Cancer
VX5 (VX5/5261) is a humanized IgG1κ monoclonal antibody inhibitor targeting BCA-1/CXCL13. VX5 significantly inhibits human CXCL13-mediated internalization of CXCR5, blocks both human and mouse CXCL13-dependent B-cells chemotaxis and migration. VX5 can be used to study autoimmune diseases like multiple sclerosis and arthritis, and cancers like gastric lymphomas and colon cancer .

HY-124416

ML604086 1 Publications Verification	CCR	Inflammation/Immunology Endocrinology
ML604086 is a selective CCR8 inhibitor, inhibiting CCL1 binding to CCR8 on circulating T-cells. ML604086 inhibits CCL1 mediated chemotaxis and increases in intracellular Ca ²⁺ concentrations .

HY-126536

ChemR23-IN-1	Chemerin Receptor	Inflammation/Immunology
ChemR23-IN-1 (compound 2) is a ChemR23 inhibitor with IC₅₀s of 38 nM and 100 nM for human and mouse ChemR23, respectively. ChemR23-IN-1 inhibits chemotaxis of CAL-1 triggered by Chemerin in vitro .

HY-103364

C-021 2 Publications Verification	CCR	Inflammation/Immunology
C-021 is a potent CC chemokine receptor-4 (CCR4) antagonist. C-021 potently inhibits functional chemotaxis in human and mouse with IC₅₀s of 140 nM and 39 nM, respectively. C-021 effectively prevents human CCL22-derived [ ³⁵S]GTPγS from binding to the receptor with an IC₅₀ of 18 nM .

HY-P3982

CKLF1-C19	CCR	Inflammation/Immunology
CKLF1-C19 is the C-terminal peptide of human chemokine-like factor 1 (CKLF1). CKLF1-C19 interacts with CCR4, and inhibits chemotaxis induced by both CKLF1 and CCL17. CKLF1-C19 can suppress allergic lung inflammation via inhibiting chemotaxis mediated by CCR3 and CCR4 .

HY-123763

MLN3126	CCR	Inflammation/Immunology
MLN3126 is an orally active and potent CCR9 antagonist. MLN3126 inhibits CCL25-induced calcium mobilization and chemotaxis of mouse primary thymocytes, wiht an IC₅₀ value of 6.3 nM for calcium influx .

HY-13499

JNJ-41443532 CCR2 antagonist 5	CCR	Inflammation/Immunology
JNJ-41443532 (CCR2 antagonist 5) is a selective, orally active hCCR2 inhibitor with good binding affinity (IC₅₀=37 nM) and potent functional antagonism (chemotaxis IC₅₀=30 nM). JNJ-41443532 displays a K_i of 9.6 µM for mCCR2 binding. JNJ-41443532 can be used in the research of inflammatory disease .

HY-145697

GPR84 antagonist 2	GPR84	Inflammation/Immunology
GPR84 antagonist 2 (compound 33) is a potent, selective, and orally active GPR84 antagonist (IC₅₀=8.95 nM). GPR84 antagonist 2 shows improved potency in the calcium mobilization assay and the ability to inhibit the chemotaxis of neutrophils and macrophages upon GPR84 activation. GPR84 antagonist 2 has the potential for the research of ulcerative colitis .

HY-123532

JNJ10191584 VUF6002	Histamine Receptor	Neurological Disease
JNJ10191584 (VUF6002) is an orally active and selective histamine H₄ receptor antagonist with a K_i value of 26 nM. JNJ10191584 shows 540-fold selectivity to H₄ receptor over H₃ receptor with a K_i value of 14.1 μM. JNJ10191584 inhibits chemotaxis of eosinophils and mast cells with IC₅₀ values of 530 nM and 138 nM, respectively .

HY-P4744A

LL-37 amide TFA 2 Publications Verification	Formyl Peptide Receptor (FPR) Bacterial	Infection Cancer
LL-37 amide TFA is a selective agonist of formyl peptide receptor-like FPRL1, effectively inhibiting periodontal pathogens (ED₉₉=8.5-8.7 μg/mL). LL-37 amide TFA exerts its bactericidal effect by activating FPRL1-mediated immune cell chemotaxis and disrupting bacterial cell membrane integrity. It can also regulate inflammatory responses (inhibiting the release of factors such as TNF-α) and promote angiogenesis. Amidation modification reduces its sensitivity to serum inhibition and improves its stability. LL-37 amide TFA possesses key activities in bactericidal action, immunomodulation, and wound healing, and is mainly used in research on infection-related diseases such as periodontal disease and deep tissue injuries (pressure ulcers), and wound healing .

HY-15724A

Vercirnon sodium 3 Publications Verification GSK-1605786 sodium; CCX282-B sodium; Traficet-EN sodium	CCR	Inflammation/Immunology Endocrinology
Vercirnon (GSK1605786A) sodium is an orally bioavailable, selective, and potent antagonist of CCR9. Vercirnon sodium inhibits CCR9-mediated Ca ²⁺ mobilization and chemotaxis on Molt-4 cells with IC₅₀ values of 5.4 and 3.4 nM, respectively. Vercirnon sodium is selective for CCR9 over CCR1-12 and CX3CR1-7 (IC₅₀s>10 μM for all). Vercirnon sodium is an equipotent inhibitor of CCL25-directed chemotaxis of both splice forms of CCR9 (CCR9A and CCR9B) with IC₅₀ values of 2.8 and 2.6 nM, respectively .

HY-17042S1

Cetirizine-d8	Histamine Receptor	Inflammation/Immunology
Cetirizine-d₈ is a deuterium labeled Cetirizine. Cetirizine, a second-generation antihistamine and the carboxylated metabolite of hydroxyzine, is a specific, orally active and long-acting histamine H1-receptor antagonist. Cetirizine marks antiallergic properties and inhibits eosinophil chemotaxis during the allergic response .

HY-107401

Ancriviroc SCH-351125	HIV CCR Calcium Channel	Infection
Ancriviroc (SCH-351125) is an orally active CCR5 antagonist with an IC₅₀ value of 13 nM against hCCR5. Ancriviroc specifically binds to hCCR5, blocks ligand-induced signal transduction, calcium influx, GTPγS binding, chemotaxis, ligand binding, and HIV-1 entry, induces conformational changes in CCR5, and inhibits infection and replication of R5-tropic HIV-1 .

HY-106381A

Aurothiomalate tetramer sodium	PKC TrxR NF-κB	Inflammation/Immunology Cancer
Aurothiomalate tetramer sodium is the tetrameric form of Aurothiomalate sodium (HY-106381). Aurothiomalate tetramer sodium acts as an inhibitor of PKCI and TrxR1. Aurothiomalate tetramer sodium disrupts the PKCI-Par6-Rac1 signaling pathway, and also inhibits TrxR1 activity, TNFα-induced NF-κB activation, and the expression of pro-inflammatory genes. Aurothiomalate tetramer sodium blocks Kras-mediated BASC expansion and lung tumor growth, inhibits anchorage-independent growth and tumorigenicity of lung cancer cells, and suppresses neutrophil chemotaxis, phagocytosis, and leukocyte extravasation. Aurothiomalate tetramer sodium can be used in research related to rheumatoid arthritis and non-small cell lung cancer .

HY-116116

Tafetinib SIM010603	c-Kit RET VEGFR	Cancer
Tafetinib (SIM010603) is an oral multi-targets receptor tyrosine kinases inhibitor. Tafetinib inhibitsstem cell factor receptor (Kit),vascular endothelial growth factor receptor-2 (VEGFR-2),platelet-derived growth factor receptor-β (PDGFR-β),glial cell line-derived neurotrophic factor receptor (Rearranged during Transfection; RET), andFms-like tyrosine kinase-3 (FLT3)withIC₅₀values between 5.0 and 68.1 nmol/l. Tafetinib inhibits the phosphorylation ofPDGFR-βandVEGFR-2. Tafetinib inhibits endothelial cell proliferation, endothelial cells chemotaxis, and corneal angiogenesis .

HY-N8541

Endocrocin	Endogenous Metabolite	Inflammation/Immunology
Endocrocin, an anthraquinone, is a fungal secondary metabolite. Endocrocin is a potent chemotaxis inhibitor with immunosuppressive properties .

HY-124404

12(R)-HETE	Aryl Hydrocarbon Receptor Na+/K+ ATPase Prostaglandin Receptor	Inflammation/Immunology
12(R)-HETE is a CYP-dependent arachidonic acid metabolite that acts as a proinflammatory lipid mediator. 12 (R)-HETE widely exists in various tissues including the eye, skin and liver. In the cornea, 12(R)-HETE is metabolized via pathways such as β-oxidation into the precursor of 12(R)-HETrE. Without direct receptor binding, 12(R)-HETE indirectly activates AHR-mediated target gene transcription, while inhibiting the enzymatic activity of Na+,K+-ATPase and the intracellular calcium elevation induced by TP agonists. 12(R)-HETE also possesses multiple physiological effects such as chemotaxis, proangiogenesis, vasodilation, natriuresis, diuresis and intraocular pressure reduction, and can be widely used in studies related to psoriasis, inflammatory skin diseases and ocular inflammation .

HY-155300

BLT2 antagonist-1	Leukotriene Receptor	Inflammation/Immunology
BLT2 antagonist-1 (compound 15b) is a selective BLT2 antagonist that inhibits the chemotaxis of CHO-BLT2 cells with an IC₅₀ of 224 nM. BLT2 antagonist-1 does not inhibits the chemotaxis of CHO-BLT1 cells. BLT2 antagonist-1 also inhibits the binding of LTB4 and BLT2 with a K_i value of 132 nM. BLT2 antagonist-1 can be used for the research of the inflammatory airway diseases such as asthma and chronic obstructive pulmonary disease .

HY-116230

BI-L-45 XX	Ser/Thr Protease	Inflammation/Immunology
BI-L-45 XX is an orally active anti-inflammatory agent. BI-L-45 XX can inhibit the release of neutrophil enzymes and chemotaxis, and is used in the study of adjuvant-induced arthritis .

HY-19501

DPC-168	CCR	Inflammation/Immunology
DPC-168 is an orally effective CCR3 antagonist (IC₅₀ = 41 nM). DPC-168 exhibits a significant ability to inhibit eosinophil chemotaxis and pulmonary inflammation. DPC-168 can be used for research on airway inflammation .

HY-116171

(Rac)-Calpain Inhibitor XII	Proteasome	Cardiovascular Disease Neurological Disease
(Rac)-Calpain Inhibitor XII is a reversible and selective inhibitor of calpain I (μ-calpain, K_i=19 nM). (Rac)-Calpain Inhibitor XII has lower affinities for calpain II (m-calpain, K_i=120 nM) and cathepsin B (K_i=750 nM). (Rac)-Calpain Inhibitor XII has the potential for studying the role of calpains in diverse processes, including neutrophil chemotaxis, neuronal signaling, and cardiac response to injury .

HY-125567

Antileukinate	CXCR	Inflammation/Immunology
Antileukinate, a hexapeptide, is a potent inhibitor of CXC-chemokine receptor (CXCR). Antileukinate inhibits neutrophil chemotaxis and activation. Antileukinate can be used for the research of acute inflammation and injury .

HY-P11553

ECL1i	CCR	Inflammation/Immunology
ECL1i is an allosteric, selective CCR2 inhibitor. ECL1i specifically inhibits CCL2-/CCR2-mediated chemotaxis. ECL1i interferes with CCR2-positive cell recruitment and attenuates disease progression in experimental autoimmune encephalomyelitis .

HY-P11553A

ECL1i TFA	CCR	Infection Inflammation/Immunology
ECL1i TFA is an allosteric, selective CCR2 inhibitor. ECL1i TFA specifically inhibits CCL2-/CCR2-mediated chemotaxis. ECL1i TFA interferes with CCR2-positive cell recruitment and attenuates disease progression in experimental autoimmune encephalomyelitis .

HY-17042S

Cetirizine-d4	Histamine Receptor	Inflammation/Immunology
Cetirizine-d₄ is a deuterium labeled Cetirizine. Cetirizine, a second-generation antihistamine and the carboxylated metabolite of hydroxyzine, is a specific, orally active and long-acting histamine H1-receptor antagonist. Cetirizine marks antiallergic properties and inhibits eosinophil chemotaxis during the allergic response[1][2][3].

HY-174761

Human CCL21 mRNA	mRNA	Inflammation/Immunology
Human CCL21 mRNA encodes the human C-C motif chemokine ligand 21 (CCL21) protein, a chemokine that can inhibit hemopoiesis and stimulate chemotaxis. CCL21 is chemotactic in vitro for thymocytes and activated T cells, but not for B cells, macrophages, or neutrophils. It may also play a role in mediating homing of lymphocytes to secondary lymphoid organs.

HY-160998

YM-344031	CCR	Inflammation/Immunology
YM-344031 is an orally active antagonist for CCR3. YM-344031 inhibits binding of Eotaxin-1 and RANTES to CCR3, with IC₅₀ of 3.0 and 16.3 nM. YM-344031 inhibits ligand-induced rise in intracellular Ca ^[2+] and the ligand-induced chemotaxis. YM-344031 inhibits eotaxin-1-induced changes in eosinophil morphology in macaques blood, and prevents allergic skin reactions in a mouse allergy model .

HY-107558

JNJ10191584 maleate VUF6002 maleate	Histamine Receptor	Neurological Disease
JNJ10191584 (VUF6002) maleate (compound 40) is an orally active and selective histamine H₄ receptor antagonist with a K_i value of 26 nM. JNJ10191584 maleate shows 540-fold selectivity to H₄ receptor over the H₃ receptor with a K_i value of 14.1 μM. JNJ10191584 maleate inhibits chemotaxis of eosinophils and mast cells with IC₅₀ values of 530 nM and 138 nM, respectively .

HY-125836

CCR4 antagonist 2	CCR	Endocrinology Cancer
CCR4 antagonist 2 (Compound 31) is a novel potent, orally bioavailable small molecule antagonists of CC chemokine receptor 4 (CCR4) that inhibits T_reg trafficking into the Tumor Microenvironment without suppressing the number of Treg in healthy tissues. CCR4 antagonist 2 (Compound 31) exhibits IC₅₀ values of Ca ²⁺flux and (chemotaxis) CTX are 40 nM and 70 nM, respectively .

HY-W744699

Larixol (+)-Larixol	Src ERK Akt	Inflammation/Immunology
Larixol is an fMLP inhibitor and also inhibits Src kinase, ERK1/2, p38 and AKT phosphorylation signals in immune regulation. Larixol can interfere with the interaction between the βγ subunit of the fMLP receptor Gi protein and its downstream molecules, thereby inhibiting fMLP-induced respiratory burst. Larixol inhibits fMLP (0.1 μM)-induced superoxide anion production (IC₅₀: 1.98 μM), cathepsin G release (IC₅₀: 2.76 μM), and chemotaxis. Larixol improves neutrophil hyperactivation and reduces inflammation or tissue damage. A series of Larixol derivatives were found to have inhibitory effects on FSGS-related TRPC6 functional mutants .

HY-103360B

trans-J-113863	CCR	Inflammation/Immunology
trans-J-113863 is a potent chemokine CCR1 and CCR3 receptor antagonist, and inhibits MIP-1α-induced chemotaxis in CCR1 transfectants and eotaxin-induced chemotaxis in CCR3 transfectants with IC₅₀ of 9.57 and 93.8 nM,respectively .

HY-123270

RP23618	CCR	Infection Inflammation/Immunology
RP23618 is a non peptidic RANTES antagonist with the IC₅₀ of 3 μM. RP23618 inhibit RANTES-induced chemotaxis of THP-1 cells .

Cat. No.	Product Name	Type

HY-W745090

Isomaltulose monohydrate

Biochemical Assay Reagents

Isomaltulose monohydrate is a fMLP inhibitor and also inhibits Src kinase, ERK1/2, p38 and AKT phosphorylation signals in immune regulation. Isomaltulose monohydrate can interfere with the interaction between the βγ subunit of the fMLP receptor Gi protein and its downstream molecules, thereby inhibiting fMLP-induced respiratory burst. Isomaltulose monohydrate inhibits fMLP (0.1 μM)-induced superoxide anion production (IC₅₀: 1.98 μM) , cathepsin G release (IC< sub>50: 2.76 μM) and chemotaxis. Isomaltulose monohydrate can improve excessive activation of neutrophils and reduce inflammation or tissue damage. A series of derivatives of Isomaltulose monohydrate are found to have inhibitory effects on FSGS-related TRPC6 functional mutants .

Cat. No.	Product Name	Target	Research Area

HY-P4744

LL-37 amide 2 Publications Verification	Formyl Peptide Receptor (FPR) Bacterial	Infection Cancer
LL-37 amide is a selective agonist of formyl peptide receptor-like FPRL1, effectively inhibiting periodontal pathogens (ED₉₉=8.5-8.7 μg/mL). LL-37 amide exerts its bactericidal effect by activating FPRL1-mediated immune cell chemotaxis and disrupting bacterial cell membrane integrity. It can also regulate inflammatory responses (inhibiting the release of factors such as TNF-α) and promote angiogenesis. Amidation modification reduces its sensitivity to serum inhibition and improves its stability. LL-37 amide possesses key activities in bactericidal action, immunomodulation, and wound healing, and is mainly used in research on infection-related diseases such as periodontal disease and deep tissue injuries (pressure ulcers), and wound healing .

HY-P3982

CKLF1-C19	CCR	Inflammation/Immunology
CKLF1-C19 is the C-terminal peptide of human chemokine-like factor 1 (CKLF1). CKLF1-C19 interacts with CCR4, and inhibits chemotaxis induced by both CKLF1 and CCL17. CKLF1-C19 can suppress allergic lung inflammation via inhibiting chemotaxis mediated by CCR3 and CCR4 .

HY-P4744A

LL-37 amide TFA 2 Publications Verification	Formyl Peptide Receptor (FPR) Bacterial	Infection Cancer
LL-37 amide TFA is a selective agonist of formyl peptide receptor-like FPRL1, effectively inhibiting periodontal pathogens (ED₉₉=8.5-8.7 μg/mL). LL-37 amide TFA exerts its bactericidal effect by activating FPRL1-mediated immune cell chemotaxis and disrupting bacterial cell membrane integrity. It can also regulate inflammatory responses (inhibiting the release of factors such as TNF-α) and promote angiogenesis. Amidation modification reduces its sensitivity to serum inhibition and improves its stability. LL-37 amide TFA possesses key activities in bactericidal action, immunomodulation, and wound healing, and is mainly used in research on infection-related diseases such as periodontal disease and deep tissue injuries (pressure ulcers), and wound healing .

HY-125567

Antileukinate	CXCR	Inflammation/Immunology
Antileukinate, a hexapeptide, is a potent inhibitor of CXC-chemokine receptor (CXCR). Antileukinate inhibits neutrophil chemotaxis and activation. Antileukinate can be used for the research of acute inflammation and injury .

HY-P11553

ECL1i	CCR	Inflammation/Immunology
ECL1i is an allosteric, selective CCR2 inhibitor. ECL1i specifically inhibits CCL2-/CCR2-mediated chemotaxis. ECL1i interferes with CCR2-positive cell recruitment and attenuates disease progression in experimental autoimmune encephalomyelitis .

HY-P11553A

ECL1i TFA	CCR	Infection Inflammation/Immunology
ECL1i TFA is an allosteric, selective CCR2 inhibitor. ECL1i TFA specifically inhibits CCL2-/CCR2-mediated chemotaxis. ECL1i TFA interferes with CCR2-positive cell recruitment and attenuates disease progression in experimental autoimmune encephalomyelitis .

Cat. No.	Product Name	Target	Research Area	Image

HY-P99520

Vilobelimab CaCP-29, IFX-1	Complement System SARS-CoV	Infection Inflammation/Immunology
Vilobelimab (CaCP-29, IFX-1) is a monoclonal anti-C5a antibody to the allergen C5a, a pro-inflammatory complement division product that plays a central role in mediating organ dysfunction. Vilobelimab acts as a C5a inhibitor, inhibiting neutrophil activation, chemotaxis, and reducing inflammatory signalling, and may be used in studies related to sepsis, COVID-19, etc .

HY-P991567

VX5 VX5/5261	CXCR	Inflammation/Immunology Cancer
VX5 (VX5/5261) is a humanized IgG1κ monoclonal antibody inhibitor targeting BCA-1/CXCL13. VX5 significantly inhibits human CXCL13-mediated internalization of CXCR5, blocks both human and mouse CXCL13-dependent B-cells chemotaxis and migration. VX5 can be used to study autoimmune diseases like multiple sclerosis and arthritis, and cancers like gastric lymphomas and colon cancer .

HY-P992365

HFB101110	CCR	Cancer
HFB101110 is a human-derived inhibitor and Treg depleter that specifically targets CCR8. It does not bind to the homologous CCR4 receptor and is mainly used in research on solid tumors, renal cell carcinoma and colorectal cancer. HFB101110 blocks hCCL1 binding by interacting with the N-terminal extracellular domain of hCCR8, thereby inhibiting hCCL1-induced calcium influx, chemotaxis and downstream signaling pathways. Meanwhile, HFB101110 can mediate ADCC effects to specifically deplete CCR8-positive cells, including intratumoral Tregs. HFB101110 exhibits favorable anti-tumor activity and pharmacokinetic properties .

HY-P991944

ZL-1218	CCR	Cancer
ZL-1218 is a selective humanized IgG1 antibody, targeting CCR8. ZL-1218 induces antibody-dependent cellular cytotoxicity (ADCC), leading to NK cell-mediated depletion of CCR8-expressing regulatory T cells (Tregs). ZL-1218 blocks the binding of the CCR8 ligand CCL1 to CCR8 and reduces Treg recruitment by inhibiting the chemotaxis of CCR8 ⁺ cells. ZL-1218 reduces intratumoral Treg levels in a dose-dependent manner. ZL-1218 exerts enhanced antitumor activity when combined with the anti-PD-1 antibody. ZL-1218 can be used for solid tumour research .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-17042

Cetirizine 3 Publications Verification	Classification of Application Fields Ketones, Aldehydes, Acids Endogenous metabolite Disease Research Fields Endocrinology Source Classification	Histamine Receptor
Cetirizine, a second-generation antihistamine and the carboxylated metabolite of hydroxyzine, is a specific, orally active and long-acting histamine H1-receptor antagonist. Cetirizine marks antiallergic properties and inhibits eosinophil chemotaxis during the allergic response .

HY-N0634

Cimifugin 1 Publications Verification Cimitin	Classification of Application Fields Ranunculaceae Coumarins Phenylpropanoids Plants Cimicifuga racemosa (L.) Nutt. Inflammation/Immunology Disease Research Fields	NF-κB
Cimifugin (Cimitin) is a bioactive component of Cimicifuga racemosa, a Chinese herb. Cimifugin suppresses allergic inflammation by reducing epithelial derived initiative key factors via regulating tight junctions . Cimifugin reduces the migration and chemotaxis of RAW264.7 cells and inhibits the release of inflammatory factors and activation of MAPKs and NF-κB signaling pathways induced by LPS .

HY-N8541

Endocrocin	Quinones Microorganisms Source Classification	Endogenous Metabolite
Endocrocin, an anthraquinone, is a fungal secondary metabolite. Endocrocin is a potent chemotaxis inhibitor with immunosuppressive properties .

HY-W744699

Larixol (+)-Larixol	Larix decidua Miller Natural Products Pinaceae Plants Source Classification	Src ERK Akt
Larixol is an fMLP inhibitor and also inhibits Src kinase, ERK1/2, p38 and AKT phosphorylation signals in immune regulation. Larixol can interfere with the interaction between the βγ subunit of the fMLP receptor Gi protein and its downstream molecules, thereby inhibiting fMLP-induced respiratory burst. Larixol inhibits fMLP (0.1 μM)-induced superoxide anion production (IC₅₀: 1.98 μM), cathepsin G release (IC₅₀: 2.76 μM), and chemotaxis. Larixol improves neutrophil hyperactivation and reduces inflammation or tissue damage. A series of Larixol derivatives were found to have inhibitory effects on FSGS-related TRPC6 functional mutants .

HY-17042R

Cetirizine (Standard)	Structural Classification Ketones, Aldehydes, Acids Endogenous metabolite Source Classification	Reference Standards Histamine Receptor
Cetirizine (Standard) is the analytical standard of Cetirizine. This product is intended for research and analytical applications. Cetirizine, a second-generation antihistamine and the carboxylated metabolite of hydroxyzine, is a specific, orally active and long-acting histamine H1-receptor antagonist. Cetirizine marks antiallergic properties and inhibits eosinophil chemotaxis during the allergic response .

HY-N0634R

Cimifugin (Standard) Cimitin (Standard)	Structural Classification Ranunculaceae Coumarins Phenylpropanoids Plants Cimicifuga racemosa (L.) Nutt.	Reference Standards NF-κB
Cimifugin (Standard) is the analytical standard of Cimifugin. This product is intended for research and analytical applications. Cimifugin (Cimitin) is a bioactive component of Cimicifuga racemosa, a Chinese herb. Cimifugin suppresses allergic inflammation by reducing epithelial derived initiative key factors via regulating tight junctions . Cimifugin reduces the migration and chemotaxis of RAW264.7 cells and inhibits the release of inflammatory factors and activation of MAPKs and NF-κB signaling pathways induced by LPS .

HY-N11723

Catenarin Katenarin	Quinones Microorganisms Anthraquinones Source Classification	CCR CXCR p38 MAPK JNK Calcium Channel
Catenarin, an anthraquinone compound, inhibits CCR5- and CXCR4-mediated chemotaxis. Catenarin reduces the phosphorylation of mitogen-activated protein kinases (p38 and JNK) and their upstream kinases (MKK6 and MKK7), and calcium mobilization. Catenarin shows anti-inflammatory effect and suppresses leukocyte migration in the diabetes. Catenarin exhibits significant inhibitory effects against Gram-positive bacteria. Catenarin prevents type 1 diabetes (T1D) in nonobese diabetic mice ^[1][2].

Cat. No.	Product Name	Chemical Structure

HY-17042S1

Cetirizine-d8
Cetirizine-d₈ is a deuterium labeled Cetirizine. Cetirizine, a second-generation antihistamine and the carboxylated metabolite of hydroxyzine, is a specific, orally active and long-acting histamine H1-receptor antagonist. Cetirizine marks antiallergic properties and inhibits eosinophil chemotaxis during the allergic response .

HY-17042S

Cetirizine-d4
Cetirizine-d₄ is a deuterium labeled Cetirizine. Cetirizine, a second-generation antihistamine and the carboxylated metabolite of hydroxyzine, is a specific, orally active and long-acting histamine H1-receptor antagonist. Cetirizine marks antiallergic properties and inhibits eosinophil chemotaxis during the allergic response[1][2][3].

HY-17042AS1

Cetirizine-d8 dihydrochloride
Cetirizine-d₈ (dihydrochloride) is a deuterium labeled Cetirizine. Cetirizine, a second-generation antihistamine and the carboxylated metabolite of hydroxyzine, is a specific, orally active and long-acting histamine H1-receptor antagonist. Cetirizine marks antiallergic properties and inhibits eosinophil chemotaxis during the allergic response .

HY-17042AS

Cetirizine-d4 dihydrochloride
Cetirizine-d₄ (dihydrochloride) is a deuterium labeled Cetirizine. Cetirizine, a second-generation antihistamine and the carboxylated metabolite of hydroxyzine, is a specific, orally active and long-acting histamine H1-receptor antagonist. Cetirizine marks antiallergic properties and inhibits eosinophil chemotaxis during the allergic response .

Cat. No.	Product Name		Classification

HY-174761

Human CCL21 mRNA		mRNA Chemokine & Receptors
Human CCL21 mRNA encodes the human C-C motif chemokine ligand 21 (CCL21) protein, a chemokine that can inhibit hemopoiesis and stimulate chemotaxis. CCL21 is chemotactic in vitro for thymocytes and activated T cells, but not for B cells, macrophages, or neutrophils. It may also play a role in mediating homing of lymphocytes to secondary lymphoid organs.

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

chemotaxis inhibitor

Inhibitors & Agonists

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

NaturalProducts

Isotope-Labeled Compounds

Oligonucleotides

Natural
Products